DENTSPLY SIRONA Inc.

Valuation Analysis

About the Company

DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedur

DENTSPLY SIRONA Inc. Stock at a Glance

DENTSPLY SIRONA Inc. (XRAY) is currently trading at $10.09 with a market capitalization of $2B. The 52-week range spans from $9.41 to $17.09; the current price is 41% below the yearly high. Year-over-year revenue growth stands at +0.1%.

💰 Dividend

DENTSPLY SIRONA Inc. pays an annual dividend of $0.64 per share, representing a yield of 6.34%. The payout ratio stands at 28.83%.

📊 Analyst Rating

15 analysts rate DENTSPLY SIRONA Inc. (XRAY) on consensus: Hold. The average price target is $13.40, implying +32.8% from the current price. Analyst price targets range from $9.00 to $17.00.

DENTSPLY SIRONA Inc.: The Investment Case in Detail

DENTSPLY SIRONA Inc. (XRAY) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Revenue growth has slowed to just 0.1%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 12.18% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

With a PEG ratio of 0.72, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 7.51x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The dividend yield near 6.34% combined with a payout ratio of 28.83% leaves room for further hikes — a track record of consecutive raises is a strong income signal.
• The analyst consensus price target implies 32.8% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (12.18%), higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy DENTSPLY SIRONA Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.